Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 1, 2011, Pages

  Peacock, Munro ^a   Bilezikian, J P ^b   Bolognese, M A ^c   Borofsky, Michael ^d   Scumpia, Simona ^e   Sterling, L R ^f   Cheng, Sunfa ^f   Shoback, Dolores ^g  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b College of Physicians and Surgeons ^*  (United States)

^c Bethesda Health Research Center   (United States)

^d LLP   (United States)

^e Austin Thyroid and Endocrinology   (United States)

^f AMGEN INC   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; CINACALCET; PHOSPHATE; PLACEBO;

ARTHRALGIA; ARTICLE; BLOOD ANALYSIS; BLOOD CELL COUNT; BONE DENSITY; CALCIUM BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERCALCEMIA; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; PARATHYROIDECTOMY; PARESTHESIA; PATIENT COMPLIANCE; PHOSPHATE BLOOD LEVEL; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; TREATMENT FAILURE; VITAL SIGN;

EID: 78650890053     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-1221     Document Type: Article

References (30)

1. Bilezikian JP, Potts Jr JT, Fuleihan Gel-H, Kleerekoper M, Neer R, Peacock M, Rastad J, Silverberg SJ, Udelsman R, Wells SA 2002 Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Clin Endocrinol Metab 87:5353-5361 (Pubitemid 36034328)
2. Eastell R, Arnold A, Brandi ML, Brown EM, D'Amour P, Hanley DA, Rao DS, Rubin MR, Goltzman D, Silverberg SJ, Marx SJ, Peacock M, Mosekilde L, Bouillon R, Lewiecki EM 2009 Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 94:340-350
3. Silverberg SJ, Lewiecki EM, Mosekilde L, Peacock M, Rubin MR 2009 Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 94:351-365
4. Rubin MR, Bilezikian JP, McMahon DJ, Jacobs T, Shane E, Siris E, Udesky J, Silverberg SJ 2008 The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab 93:3462-3470
5. Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP 1999 A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med 341:1249-1255 (Pubitemid 29489739)
6. Udelsman R, Pasieka JL, Sturgeon C, Young JE, Clark OH 2009 Surgery for asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 94:366-372
7. Peacock M 2002 Primary hyperparathyroidism and the kidney: biochemical and clinical spectrum. J Bone Miner Res 17(Suppl 2):N87-N94
8. Hagström E, Lundgren E, Mallmin H, Rastad J, Hellman P 2006 Positive effect of parathyroidectomy on bone mineral density in mild asymptomatic primary hyperparathyroidism. J Intern Med 259:191-198
9. Diamond T, Ng AT, Levy S, Magarey C, Smart R 1996 Estrogen replacement may be an alternative to parathyroid surgery for the treatment of osteoporosis in elderly postmenopausal women presenting with primary hyperparathyroidism: a preliminary report. Osteoporos Int 6:329-333
10. Grey AB, Stapleton JP, Evans MC, Tatnell MA, Reid IR 1996 The effect of hormone replacement therapy on bone mineral density in postmenopausalwomenwith mild primary hyperparathyroidism.A randomized, controlled trial. Ann Intern Med 125:360-368
11. Rubin MR, Lee KH, McMahon DJ, Silverberg SJ 2003 Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 88:1174-1178
12. Khan AA, Bilezikian JP, Kung AW, Ahmed MM, Dubois SJ, Ho AY, Schussheim D, Rubin MR, Shaikh AM, Silverberg SJ, Standish TI, Syed Z, Syed ZA 2004 Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab 89:3319-3325
13. Tal A, Graves L 1996 Intravenous pamidronate for hypercalcemia of primary hyperparathyroidism. South Med J 89:637-640 (Pubitemid 26172698)
14. Brown EM, Gamba G, Riccardi D, Lombardi M, Butters R, Kifor O, Sun A, Hediger MA, Lytton J, Hebert SC 1993 Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature 366:575-580 (Pubitemid 24035999)
15. Nemeth EF, Fox J 1999 Calcimimetic compounds: a direct approach to controlling plasma levels of parathyroid hormone in hyperparathyroidism. Trends Endocrinol Metab 10:66-71 (Pubitemid 29287825)
16. Marcocci C, Chanson P, Shoback D, Bilezikian J, Fernandez-Cruz L, Orgiazzi J, Henzen C, Cheng S, Sterling LR, Lu J, Peacock M 2009 Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism. J Clin Endocrinol Metab 94:2766-2772
17. Peacock M, Bilezikian JP, Klassen PS, Guo MD,Turner SA, Shoback D 2005 Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 90:135-141
18. Shoback DM, Bilezikian JP, Turner SA, McCary LC, Guo MD, Peacock M 2003 The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J Clin Endocrinol Metab 88:5644-5649
19. Peacock M, Bolognese MA, Borofsky M, Scumpia S, Sterling LR, Cheng S, Shoback D 2009 Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study. J Clin Endocrinol Metab 94:4860-4867
20. Silverberg SJ, Rubin MR, Faiman C, Peacock M, Shoback DM, Smallridge RC, Schwanauer LE, Olson KA, Klassen P, Bilezikian JP 2007 Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. J Clin Endocrinol Metab 92:3803-3808
21. Harris RZ, Padhi D, Marbury TC, Noveck RJ, Salfi M, Sullivan JT 2004 Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily. Am J Kidney Dis 44:1070-1076
22. Houillier P, Paillard M 2003 Calcium-sensing receptor and renal cation handling. Nephrol Dial Transplant 18:2467-2470
23. Chang W, Tu C, Chen TH, Komuves L, Oda Y, Pratt SA, Miller S, Shoback D 1999 Expression and signal transduction of calcium-sensing receptors in cartilage and bone. Endocrinology 140:5883-5893
24. Riccardi D, Traebert M, Ward DT, Kaissling B, Biber J, Hebert SC, Murer H 2000 Dietary phosphate and parathyroid hormone alter the expression of the calcium-sensing receptor (CaR) and the Na+-dependent Pi transporter (NaPi-2) in the rat proximal tubule. Pflugers Arch 441:379-387
25. Wetmore JB, Liu S, Krebill R, Menard R, Quarles LD 2010 Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. Clin J Am Soc Nephrol 5:110-116
26. Kawata T, Imanishi Y, Kobayashi K, Miki T, Arnold A, Inaba M, Nishizawa Y 2007 Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J Am Soc Nephrol 18:2683-2688
27. Frolik CA, Black EC, Cain RL, Satterwhite JH, Brown-Augsburger PL, Sato M, Hock JM 2003 Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure. Bone 33:372-379
28. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441
29. Bouxsein ML, Pierroz DD, Glatt V, Goddard DS, Cavat F, Rizzoli R, Ferrari SL 2005 β-Arrestin 2 regulates the differential response of cortical and trabecular bone to intermittent PTH in female mice. J Bone Miner Res 20:635-643
30. 2+-sensing receptor promotes loss of cancellous bone. Endocrinology 148:3156-3163